Navigation Links
Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Date:3/5/2008

OMAHA, Neb., March 5 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a leading global genetic analysis company, today announced that it has entered into agreements with two major Pharmaceutical companies for three Phase II trials representing more than $500,000 in the first half of 2008.

"These new contracts and our growing pharmaceutical partnerships and project commitments reflect increasing customer validation of our unique mutation discovery and detection service capabilities," said Craig Tuttle, Transgenomic President and Chief Executive Officer. "We are focused on generating continued strong momentum in our Pharmacogenomics business and will continue fueling this growth through the recent addition of new business development professionals to expand our selling efforts. To complement our mutation detection expertise, we also have strong capabilities in biomarker development and mutation detection in cancer pathway genes which will aid in the development of true personalized medicine for our pharma partners."

About Transgenomic:

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, Transgenomic Molecular Clinical Reference Laboratory and Pharmacogenomics Research Services. Transgenomic's two laboratory services divisions utilize these technologies and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinic
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
2. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
3. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
6. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
7. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
8. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
9. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... -- Packaging Coordinators, Inc. (PCI) is pleased to announce it ... Services Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... United Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug ... form manufacturing, as well as Clinical Packaging, Labeling, and ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... imaging,(BSGI) is effective in the detection of cancers not ... study presented today at the annual meeting of,the Radiological ... "BSGI can identify the most difficult ... F. Brem, M.D., professor of,radiology and director of the ...
... Horizon Therapeutics, Inc., a,privately held biopharmaceutical ... 3 trials evaluating its lead investigational ... HZT-501, a novel, proprietary fixed-dose,combination product ... significant reduction in the incidence of ...
Cached Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4
(Date:7/30/2014)... 30, 2014 Hamilton Facial Plastic ... its new Carmel office on July 30th. After months ... be moving to the state-of-the-art suite, located only steps ... space will allow for one-on-one patient comfort, shorter wait ... , Dr. Hamilton’s new office-suite will continue to ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... 2014. A new network of 25 regional stroke centers ... (NIH StrokeNet) is working to change the way ... advances of the last two decades, stroke remains a ... or disability for 795,000 Americans. The numbers are expected ... , To accelerate the pace of progress, NIH ...
(Date:7/30/2014)... July 30, 2014 The Technology Association ... Alliance of TAG (B&TA), today issued its final call ... Awards. , Interested companies have until August 29th 2014 ... Semi-Finalists will be selected by the Excalibur Judging Committee. ... meet with the judges for interviewing process. , ...
(Date:7/30/2014)... 2014 Over 630 doctors worldwide are ... the revolutionary minimally invasive treatment for gum recession. Santa ... of his peers to be the “father of microsurgery” ... recent Chao Pinhole Surgical Technique® training course at the ... the recipient of the American Academy of Periodontics (AAP) ...
Breaking Medicine News(10 mins):Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2
... the form of a throat spray, researchers say , TUESDAY, ... may someday be able to avoid a tonsillectomy and get ... potentially dangerous snoring, new research suggests. , In a report ... Respiratory and Critical Care Medicine , researchers say that they,ve ...
... ... Human Services uses Percussion Community Marketing Solution to implement President Obama’s Open Government ... ... Health and Human Services is using Percussion Software’s Web Content Management System and ...
... , , SAN DIEGO , Feb. 10 ... dreams are attainable.  Back in the third quarter of 2006, 62% of ... achieving their personal dreams.  Now 55% of Americans feel this way.  On ... chance or it is impossible for them to achieve their dreams – ...
... Lou ... President of Product Marketing. , ... Charlottesville, VA (PRWEB) Feb. 29, 2010 -- Silverchair Learning Systems (SLS), the leading online education ... Robinson has joined the company as its Director of Home Health Clinical Content, and Vince ...
... ... has received a two-year grant from Merck & Co., Inc. to launch the Journey ... the EDGE Program is to improve diabetes education by enhancing the role of state ... Diabetes Conversation Maps. , ...
... , ... network announces a limited offering of free listings on its popular values-based therapist directory. ... on the directory is limited and the offering expires February 19th, 2010. , ... Olympia, WA (PRWEB) February 10, 2010 -- ...
Cached Medicine News:Health News:Web Content Management Enables Government Transparency, Participation, and Collaboration Online 2Health News:Web Content Management Enables Government Transparency, Participation, and Collaboration Online 3Health News:Web Content Management Enables Government Transparency, Participation, and Collaboration Online 4Health News:Luth Research's IndicatorEDG(TM) Study Finds Americans' Hopes of Achieving Their Dreams Are Fading 2Health News:Luth Research's IndicatorEDG(TM) Study Finds Americans' Hopes of Achieving Their Dreams Are Fading 3Health News:Luth Research's IndicatorEDG(TM) Study Finds Americans' Hopes of Achieving Their Dreams Are Fading 4Health News:Silverchair Learning Systems Enhances Product Expertise with New Hires 2Health News:NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education 2Health News:NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education 3Health News:Theravive.com Offers A Free Therapist Listing For Credentialed Counselors and Psychologists 2Health News:Theravive.com Offers A Free Therapist Listing For Credentialed Counselors and Psychologists 3
... Focus multichannel pipettes speed ... reagents into microplates, with ... l volumes. The improved ... Focus multichannels, combined with ...
... rows, and microplatesthat is the area of ... becoming an ever-increasing force. Ergonomics (reduced weight ... reason that the Multichannel Research model was ... provides effective, precise, and rapid processing of ...
... Hall, the aortic and mitral valves are distinctly ... the disc opens to 75 to maximize forward ... to minimize regurgitation. Designed to rotate within its ... the leading edge of the disc parallel to ...
Inquire...
Medicine Products: